ePT--the Electronic Newsletter of Pharmaceutical Technology, Nov 8, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Nov 8, 2012
News
Watson Completes Acquisition of Actavis, Will Take Actavis Name
By Patricia Van Arnum
Watson Pharmaceuticals has completed its EUR 4.25 billion ($5.4 billion) acquisition of the Actavis Group. The combination creates the world's third largest generic-drug pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion, according to Watson.
Boehringer Ingelheim Settles False Claims Act Allegations for $95 Million
By Amy Ritter
Boehringer Ingelheim has agreed to pay $95 million to settle allegations that it improperly promoted four of its drugs.
USP Changes Heparin Labeling Requirement
By Susan Haigney
USP revises labeling requirements for Heparin.
EC Approves Europe's First Gene Therapy
By Stephanie Sutton
The European Commission has issued final approval for Europe's first gene therapy—a treatment for a rare genetic disorder that currently has no other treatment options.
Week of November 5, 2012: Merck & Co. Resolves Vioxx Lawsuit; Takeda Agrees to Acquire Envoy Therapeutics; and More
Merck & Co. Resolves Vioxx Lawsuit; Takeda Agrees to Acquire Envoy Therapeutics; and More.
Regulatory Roundup for Week of November 5, 2012
FDA pushes back goals due to Hurricane Sandy and EMA announces changes to variation regulations.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Click here